Founded in 2017 by Harvard Medical School professors, our company leverages over 90 patents for the world’s FIRST-in-class automated exosome production technology. We have empowered more than 500 top-tier research institutes and CGT manufacturers—including Harvard Medical School, Stanford Medicine, UC Berkeley, UCLA, and numerous leading biopharma companies—to advance their scientific breakthroughs.

Validated by our industry-exclusive Nature Methods publication (February 2021), our brand, Exosomax, establishes the gold standard for exosome purity and yield. By combining rigorous scientific expertise with cutting-edge GMP production, we are relentlessly dedicated to delivering the purest exosomes to support versatile anti-aging applications.